MedPath

Pharmacokinetics of Ciprofloxacin in Pediatric Patients

Phase 4
Completed
Conditions
Urinary Tract Infection
Pyelonephritis
Interventions
Registration Number
NCT02598362
Lead Sponsor
University Hospital, Ghent
Brief Summary

Measuring serum and urine concentrations of ciprofloxacin after IV and oral administration in children aged 3 months - 17 years who are treated for urinary tract infections.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
22
Inclusion Criteria
  • age between 3 months and 17 years of age
  • confirmed diagnosis of febrile urinary tract infection (a rectal body temperature of 38.5 °C.in combination with either significant leukocyturia or a positive urine nitrite test in a reliable urine sample.
  • indication for treatment or uroprophylaxis with ciprofloxacin at discretion of the treating physician.
Exclusion Criteria
  • pregnancy
  • impaired renal function as defined by 2x serum creatinine level for age and sex
  • epilepsy
  • myasthenia gravis
  • long QT-syndrome
  • glucose 6 phosphatase deficiency (G6PD)
  • allergy to one of the substances of cipro
  • concomitant use of corticosteroids
  • for the oral group: co medication of antacidic drugs, ferrofumarate, calcium, magnesium or Zinc supplements.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
intravenousciprofloxacinParticipants who are treated with ciprofloxacin intravenously, at discretion of the treating physician.
oralciprofloxacinParticipants who are treated with ciprofloxacin via the oral route, at discretion of the treating physician.
Primary Outcome Measures
NameTimeMethod
Serum concentrations12 hours
Secondary Outcome Measures
NameTimeMethod
Urine concentrations12 hours

Trial Locations

Locations (2)

Universitair Ziekenhuis Brussel

🇧🇪

Brussel, Belgium

Ghent University Hospital

🇧🇪

Ghent, Belgium

© Copyright 2025. All Rights Reserved by MedPath